Regulatory Signal: Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration Advisory Committees | Federal Register, Document No. 2026-05623, March 23, 2026 | Docket No. FDA-2026-N-2364 | Comment Deadline: May 22, 2026
Most Federal Register notices go unread by medical device manufacturers. They look like administrative paperwork, published quietly, and expire without comment. This one deserves a second look.
On March 23, 2026, FDA published a notice in the Federal Register announcing a proposed collection of information related to FDA Advisory Committee Membership Applications (OMB No. 0910-0833). The comment deadline is May 22, 2026. On the surface, this reads as routine bureaucracy: the Paperwork Reduction Act requires FDA to publish these collection notices every three years to renew authorization. The current collection's OMB authorization expires August 31, 2026, so FDA is on schedule.
But if you manufacture, develop, or seek clearance for medical devices in the United States, the machinery being renewed here sits at the center of how major FDA policy decisions get made. Advisory committees reviewed the evidence base that underpinned the QMSR final rule. Advisory committee panels evaluate 510(k) submissions and PMAs when FDA needs independent clinical judgment. And the conflict-of-interest framework governing who sits on those panels directly shapes whether the voices shaping FDA guidance reflect the industry you compete in.
This article explains exactly what the FDA is doing, why it matters for your business, and what the comment opportunity actually means for the medical device industry.
What FDA Is Proposing: A Plain-Language Explanation
The Paperwork Reduction Act of 1995 (PRA) requires federal agencies to obtain approval from the Office of Management and Budget (OMB) before collecting information from the public. When an existing collection is up for renewal, the agency must publish a notice in the Federal Register and allow 60 days for public comment. That is precisely what this notice is.
The collection in question covers the FDA Advisory Committee Membership Application process. This is how FDA recruits, vets, and appoints the scientists, clinicians, engineers, and industry representatives who serve on its advisory panels. When someone applies to serve on an FDA advisory committee, they submit information to FDA about their background, expertise, and financial interests. FDA uses that information to evaluate their qualifications and screen for potential conflicts of interest.
The specific OMB collection being renewed here is OMB Control Number 0910-0833, expiring August 31, 2026. The proposed action is an extension, not a modification. FDA is not changing what information it collects or how it uses it. It is asking for renewed authorization to continue collecting the same information it has been collecting under this control number.
The docket number is FDA-2026-N-2364. If you want to comment, you can do so through regulations.gov referencing this docket, or by contacting the FDA Dockets Management Staff at 240-402-7500, between 9 a.m. and 4 p.m. Monday through Friday.
FDA Advisory Committees: What They Are and Why They Matter
Advisory committees are independent expert panels that FDA convenes to get outside scientific and clinical perspectives on complex questions. They do not make final decisions. FDA makes final decisions. But advisory committees provide recommendations, and those recommendations carry significant weight. A device or drug that receives a favorable advisory committee vote has a substantially higher likelihood of approval. An unfavorable vote does not automatically block approval, but it raises the bar considerably for the agency to go the other direction.
Think of advisory committees as the mechanism by which FDA injects peer review and external expertise into its regulatory decision-making. When a novel device raises questions that cannot be resolved purely through internal review, FDA can convene a panel meeting, present the data, hear from the sponsor, and ask the committee for its recommendations. The committee's deliberations become part of the public record.
The practical significance for manufacturers is direct. If your device is headed for an advisory committee meeting, the composition of that panel matters. The questions committee members ask, the clinical experience they bring, and the standards they apply to evidence will shape the outcome of your submission. Understanding who sits on these committees, how they are selected, and what rules govern their participation is not academic knowledge. It is regulatory strategy.
CDRH's Medical Devices Advisory Committee: The 18 Panels That Cover Your Device
The Center for Devices and Radiological Health (CDRH) maintains 5 standing advisory committees. The largest and most directly relevant to medical device manufacturers is the Medical Devices Advisory Committee (MDAC).
The MDAC consists of 18 panels, each dedicated to a specific medical specialty area. Together these panels cover the full spectrum of device categories that CDRH regulates. The 18 panels include:
- Anesthesiology and Respiratory Therapy Devices
- Circulatory System Devices
- Clinical Chemistry and Clinical Toxicology Devices
- Dental Products
- Ear, Nose, and Throat Devices
- Gastroenterology and Urology Devices
- General and Plastic Surgery Devices
- General Hospital and Personal Use Devices
- Hematology and Pathology Devices
- Immunology Devices
- Microbiology Devices
- Molecular and Clinical Genetics Devices
- Neurological Devices
- Obstetrics and Gynecology Devices
- Ophthalmic Devices
- Orthopedic and Rehabilitation Devices
- Radiology Devices
- Surgical and Infection Control Devices
If your company makes a cardiac monitor, a surgical robot, a neurological stimulator, or a molecular diagnostic device, there is a specific panel within the MDAC structure that would review it. These panels meet publicly. Their proceedings are transcribed. And the membership application process described in this Federal Register notice is the front door to getting qualified people onto those panels.
Beyond CDRH, other FDA centers maintain their own advisory committees covering drugs, biologics, food, and veterinary products. The membership application information collection in this notice covers all FDA advisory committees, not just those within CDRH. But from a medical device standpoint, the MDAC panels are the most operationally relevant.
The Conflict of Interest Framework: What It Means for Industry Participation
This is where the notice gets interesting for people who deal with regulatory strategy.
When an individual applies to serve on an FDA advisory committee, they disclose three categories of financial information: financial holdings, employment, and research grants and contracts. FDA uses this information to conduct a conflict of interest screening before each meeting. The question FDA is asking is whether the committee member has a financial interest in the subject matter being discussed at that specific meeting.
Two categories of committee members exist under this framework, and they operate under very different rules.
Voting members who are special government employees (SGEs) are subject to federal conflict of interest statutes. These are the standard scientific and clinical experts who serve on panels in their personal capacity. If they hold stock in a company whose device is being reviewed, they generally cannot participate in that meeting.
Industry representative members are different. They are not special government employees and are not subject to the same federal conflict of interest laws. They represent industry perspectives, and FDA explicitly recognizes that their value to the committee comes precisely from their deep familiarity with industry practice. The expectation is that they will have industry relationships.
For each meeting, FDA still reviews every member's financial interests against the specific agenda topics. The question is not whether a conflict exists in the abstract, but whether it is substantial enough to warrant exclusion. FDA can grant a waiver if:
- the member's financial interest is not substantial,
- the potential conflict is too remote or inconsequential to affect the integrity of the committee's work, or
- the member's participation is so important to the committee's function that it outweighs the potential conflict.
That third category is worth examining. When FDA determines that someone's expertise is sufficiently valuable, the agency can approve their participation even in the presence of a financial interest. This is not a loophole. It reflects the practical reality that the most qualified experts in narrow technical domains often have financial relationships with the companies that develop technology in those domains. Building advisory committees exclusively from people with no industry exposure would hollow out the scientific quality of the panels.
What this framework means for manufacturers is this: the people most likely to serve on the panels reviewing your devices are the same people who understand your technology, have consulted for companies like yours, and have formed views about the state of evidence in your field. That is a two-edged reality. A panel composed of deeply experienced clinicians and engineers is more likely to ask the right questions and evaluate your data on its scientific merits. It also means the panel will see through a weak submission faster than a less experienced group would.
Why This Notice Matters Now: The QMSR Connection
The timing of this notice is worth noting. FDA's Quality Management System Regulation (QMSR), which aligns 21 CFR Part 820 with ISO 13485:2016, became effective February 2, 2026. This is the most significant change to FDA's medical device quality management requirements in decades.
The QMSR did not materialize out of thin air. The rulemaking process spanned years and involved substantial input from multiple advisory sources, including FDA's Device Good Manufacturing Practice Advisory Committee (DGMP). That committee's role in reviewing GMP policy, evaluating proposed regulatory changes, and advising FDA on implementation practicality was part of the foundation that made the QMSR possible.
The connection between advisory committee infrastructure and major rulemaking like the QMSR is not a coincidence. Advisory committees are how FDA builds the external scientific and industry consensus needed to justify significant regulatory changes. When FDA proposes a rule that will affect every medical device manufacturer in the country, the advisory committee process provides the external validation mechanism. The quality of that process depends entirely on the quality of the membership application system.
That means the information collection being renewed in this notice is not just administrative overhead. It is part of the regulatory machinery that produced the QMSR, and that will produce whatever comes after it. Future guidance on artificial intelligence in devices, on in vitro diagnostics, on software as a medical device, and on post-market surveillance requirements will all be shaped by the committees whose membership this application process governs.
For anyone building or maintaining an ISO 13485-compliant QMS under the new QMSR framework, the advisory committee system is the long-cycle input that shapes the regulatory environment your QMS must respond to. Paying attention to who serves on these panels, and what authority structures govern their work, is part of maintaining regulatory awareness as a core QMS function.
How Advisory Committee Decisions Affect Your Device Submissions
Not every 510(k) or PMA goes to an advisory committee. The majority do not. FDA refers submissions to advisory panels when the device raises novel questions about safety or effectiveness that would benefit from independent expert review, when the device is first of its kind in a category, when there are scientific controversies about the evidence base, or when FDA determines that public transparency in the review process is warranted.
When your submission does get referred, the advisory committee process unfolds in a structured way. FDA staff present their analysis. The device sponsor has the opportunity to present data. The panel deliberates. And then the committee votes on specific questions that FDA has framed, typically around safety and effectiveness, and sometimes around specific conditions of approval or special controls.
The practical implications for manufacturers are several.
Panel composition determines the lens through which your data is evaluated. A panel that includes members with deep software expertise will scrutinize your algorithm validation differently than a panel primarily composed of clinical practitioners. This matters for submission preparation. If you know your device is likely to go to a specific panel, you should understand who sits on that panel and what their professional backgrounds are. That knowledge should influence how you frame your evidence, which expert witnesses you bring to a panel meeting, and what questions you anticipate.
Advisory committee precedent shapes future submissions. When a panel takes a position on what constitutes adequate clinical evidence for a device category, that position does not apply only to the submission being reviewed. It creates informal precedent that FDA reviewers and future applicants both consider. If the MDAC's Neurological Devices panel concludes that a certain type of clinical study design is insufficient for a brain stimulation device, that view will influence how FDA evaluates the next submission in that category, and how savvy manufacturers design their clinical programs.
Adverse advisory committee recommendations are recoverable, but costly. FDA occasionally approves devices over advisory committee objections, citing specific reasons why the agency disagrees with the panel's analysis. But the path from an unfavorable committee vote to approval is longer, more expensive, and more uncertain than the path from a favorable vote. Manufacturers who arrive at a panel meeting underprepared, or who bring a technically incomplete submission, face a difficult recovery scenario.
What the Comment Opportunity Actually Means
The public comment period on this notice closes May 22, 2026. Under the Paperwork Reduction Act, FDA is soliciting feedback on four specific questions: whether the proposed collection is necessary for FDA's functions; the accuracy of FDA's estimate of the burden the collection imposes on respondents; whether there are ways to enhance the quality, utility, and clarity of the information collected; and whether the burden of the collection can be reduced without compromising its utility.
The most actionable comment opportunity here is the third category: quality, utility, and clarity. If you have experience with the advisory committee application process, either as an applicant or as someone who works with committee members, you have direct knowledge of whether the current application process elicits the information that actually matters for conflict of interest screening, and whether the process creates friction that discourages qualified candidates from applying.
Consider what happens when the membership application process is burdensome or unclear. Qualified clinicians and engineers with relevant technical expertise may opt out. The path of least resistance is not to apply. If the application process is perceived as opaque or cumbersome, the people with the deepest practical knowledge of device technology and clinical application are the ones most likely to decline. What you end up with is advisory committees that are easier to populate but less technically qualified to evaluate the submissions they review.
From an industry standpoint, that is a bad outcome. Device manufacturers benefit from technically rigorous advisory committee review. A panel that understands your technology deeply, even if it asks hard questions, produces better regulatory outcomes than a panel that approves things it does not fully understand. The former gives you clear guidance on what FDA expects. The latter creates the kind of post-market enforcement uncertainty that nobody wants.
Submitting a comment does not require legal expertise or regulatory counsel. The regulations.gov system accepts plain-language submissions. A comment that identifies a specific friction point in the application process and offers a concrete suggestion for improving it serves the public record and gives FDA actionable input.
Strategic Implications for Medical Device Companies
There are three strategic moves worth considering in light of this notice.
First, map your device portfolio against the 18 MDAC panels. Know which panel would review your device if FDA refers it to committee. Study the current membership of that panel. Understand the backgrounds, publication records, and professional positions of the people who would evaluate your submission. This is not information that requires any special access. Advisory committee member lists are publicly available on FDA's website. Building this kind of panel-level intelligence into your regulatory strategy pays dividends well before you ever file a submission.
Second, consider whether qualified people from your organization or your professional network should apply for committee membership. Industry representative positions on FDA advisory committees are legitimate pathways for experienced industry professionals to contribute to the regulatory process. Service on an advisory committee requires disclosure and time, but it also provides direct insight into how FDA approaches evidence evaluation, what the agency's current thinking is on specific device categories, and how regulatory standards are evolving. Companies that have former advisory committee members on staff or on retainer often have a regulatory intelligence advantage that is hard to replicate otherwise.
Third, embed advisory committee monitoring into your regulatory affairs function. Treat advisory committee meeting transcripts and vote records as primary regulatory intelligence. When a panel takes a position on clinical evidence standards, software validation, or post-market surveillance design for your device category, that position should be reflected in your technical documentation strategy, your QMS procedures for managing regulatory requirements, and your submission planning timelines.
Under ISO 13485:2016 clause 4.1, your organization must determine the regulatory requirements applicable to its medical devices. That determination is not a one-time activity. Regulatory requirements evolve through advisory committee precedent, FDA guidance documents, and informal signals from the review process. A QMS that monitors those signals, captures them, and routes them to the right decision-makers is operating at a higher maturity level than one that only responds to formal rule changes.
Practical Guidance for Medical Device Companies
If you want to act on this notice before the May 22, 2026 deadline, here is what matters most.
Review the Federal Register notice directly at Document No. 2026-05623. The full text describes the collection, its purpose, and the specific questions FDA is asking for comment on. It takes about ten minutes to read.
If your regulatory affairs team or external counsel has worked with advisory committee applications, gather their observations. What parts of the application process create unnecessary friction? What information does FDA collect that seems redundant or imprecise? What information does FDA not collect that would actually improve conflict of interest screening? These are the kinds of observations that make for useful comments.
If you have no direct experience with the application process, consider commenting on the broader point about committee composition and the downstream effects on submission review quality. FDA is explicitly asking whether the collection can be enhanced. A comment that articulates the connection between application process quality and committee expertise quality serves the rulemaking record.
For companies navigating a QMSR implementation alongside active submissions, the advisory committee landscape is a factor in timing decisions. If your device is in a category where FDA has recently convened panel meetings, review those meeting transcripts. The questions committee members asked, and the positions they took, are the clearest signal available about what FDA's current standard of evidence looks like for devices like yours.
For a deeper look at how FDA's quality management requirements fit together in the post-QMSR environment, our article on the FDA QMSR and ISO 13485 alignment covers the substantive compliance changes in detail.
Act Before May 22, 2026
The comment deadline is May 22, 2026. After that date, the comment record closes and FDA proceeds with the renewal. This is a narrow window that most manufacturers will let pass without acting on it.
That is a reasonable choice if the advisory committee process has no bearing on your submissions. It is a less reasonable choice if your device is in a category where panel review is plausible, or where FDA guidance in recent years has been actively shaped by advisory committee input.
To submit a comment: go to regulations.gov, search for Docket No. FDA-2026-N-2364, and follow the submission instructions. Alternatively, contact the FDA Dockets Management Staff at 240-402-7500 between 9 a.m. and 4 p.m., Monday through Friday.
If you have questions about how your QMS should be tracking FDA advisory committee developments, or how to integrate regulatory intelligence monitoring into your ISO 13485 quality management processes, Certify Consulting can help. Jared Clark and the Certify Consulting team work with medical device manufacturers at every stage of the regulatory lifecycle, from initial QMS design through submission preparation and post-market surveillance. Schedule a free consultation to discuss your situation.
About the Author
Jared Clark, JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, RAC is the Principal Consultant at Certify Consulting, where he has guided 200+ medical device manufacturers through FDA submissions, ISO 13485 certification, and regulatory compliance strategy, with a 100% first-time audit pass rate over 8+ years of practice. Jared specializes in QMS strategy, technical documentation, and FDA regulatory compliance for medical device companies from startup to enterprise scale.
Last updated: 2026-04-08
Source: FDA Federal Register Notice, Document No. 2026-05623, Docket No. FDA-2026-N-2364, March 23, 2026
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.